Research programme: Neurodegenerative disorders therapeutics - Alzheimer's Drug Discovery Foundation/Pfizer Centers for Therapeutic Innovation

Drug Profile

Research programme: Neurodegenerative disorders therapeutics - Alzheimer's Drug Discovery Foundation/Pfizer Centers for Therapeutic Innovation

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alzheimers Drug Discovery Foundation; Pfizer Centers for Therapeutic Innovation
  • Developer Alzheimers Drug Discovery Foundation; Johns Hopkins University School of Medicine; Pfizer Centers for Therapeutic Innovation
  • Class Antidementias; Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 03 Oct 2017 Early research in Neurodegenerative disorders in USA
  • 03 Oct 2017 Early research in Parkinson's disease in USA
  • 03 Oct 2017 Pfizer Centers for Therapeutic Innovation and Alzheimer's Drug Discovery Foundation agree to co-develop drugs for Alzheimer's disease, Parkinson's disease and Neurodegenerativedisorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top